Abstract
Bone disease is highly prevalent in patients with chronic kidney disease (CKD), leading to an increased risk of bone fractures. This is due in part to metabolic acid-induced bone dissolution. Bisphosphonates (BPPs) are a potential treatment for inhibiting bone dissolution; however, there are limited studies observing the use of BPPs on acidotic patients. We aimed to determine efficacy of BPPs on maintaining bone health and pH regulation in acid-exposed mice. Using a diet-induced murine model of metabolic acidosis, we examined bone structure, composition, and mechanics as well as blood gases for three groups: control, acidosis, and acidosis + bisphosphonates (acidosis+BPP). Acidosis was induced for 14 days and alendronate was administered every 3 days for the acidosis+BPP group. The administration of BPP had little to no effect on bone structure, mechanics, and composition of the acidosis bones. However, administration of BPP did cause the mice to develop more severe acidosis than the acidosis only group. Overall, we discovered that BPPs may exacerbate acidosis symptoms by inhibiting the release of buffering ions from bone. Therefore, we propose that BPP administration should be carefully considered for those with CKD and that alkali supplementation could help minimize acidifying effects.
Funder
University of Connecticut Health Center
Division of Materials Research
University of Connecticut
National GEM Consortium
Publisher
Public Library of Science (PLoS)
Reference34 articles.
1. Rapid cortical bone loss in patients with chronic kidney disease;T.L. Nickolas;J. Bone Miner. Res,2013
2. Evaluation of fracture risk in chronic kidney disease;P.A.U. Torres;J. Nephrol,2017
3. Pamidronate-induced nephrotoxic tubular necrosis—a case report, Clin;S. Smetana;Nephrol,2004
4. Renal Failure with the Use of Zoledronic Acid, N;Engl. J. Med,2003